852323-76-3Relevant articles and documents
Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl] -4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist
Palucki, Brenda L.,Park, Min K.,Nargund, Ravi P.,Ye, Zhixiong,Sebhat, Iyassu K.,Pollard, Patrick G.,Kalyani, Rubana N.,Tang, Rui,MacNeil, Tanya,Weinberg, David H.,Vongs, Aurawan,Rosenblum, Charles I.,Doss, George A.,Miller, Randall R.,Stearns, Ralph A.,Peng, Qianping,Tamvakopoulos, Constantin,McGowan, Erin,Martin, William J.,Metzger, Joseph M.,Shepherd, Cherrie A.,Strack, Alison M.,MacIntyre, D. Euan,Van Der Ploeg, Lex H.T.,Patchett, Arthur A.
, p. 171 - 175 (2005)
We report the discovery and optimization of substituted 2-piperazinecarboxamides as potent and selective agonists of the melanocortin subtype-4 receptor. Further in vivo development of lead agonist, MB243, is disclosed.
MELANOCORTIN RECEPTOR AGONISTS
-
Page/Page column 29, (2010/02/11)
The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.